Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNFT GENFIT	$3.85 +0.1%	$4.06	$2.55 ▼ $6.42	$191.76M	1.08	10,309 shs	3,736 shs
GYRE Gyre Therapeutics	$7.39 -0.3%	$8.66	$6.11 ▼ $19.00	$694.74M	1.72	130,352 shs	118,009 shs
IMNM Immunome	$10.45 +8.1%	$8.77	$5.15 ▼ $16.81	$841.41M	1.92	910,264 shs	1.25 million shs
VIR Vir Biotechnology	$5.49 +1.5%	$5.13	$4.32 ▼ $14.45	$747.87M	1.22	1.37 million shs	1.28 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNFT GENFIT	+2.25%	+4.40%	-6.34%	+11.02%	-13.06%
GYRE Gyre Therapeutics	+3.49%	-7.38%	-7.72%	-16.55%	-52.83%
IMNM Immunome	+15.12%	+8.77%	+1.36%	+22.25%	-34.04%
VIR Vir Biotechnology	+2.08%	-8.77%	+3.24%	-1.64%	-47.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNFT GENFIT	2.185 of 5 stars	3.5	5.0	1.7	0.0	0.0
GYRE Gyre Therapeutics	0.113 of 5 stars	0.0	1.0	2.2	0.8	0.0
IMNM Immunome	2.1531 of 5 stars	3.5	0.0	4.0	2.5	0.0
VIR Vir Biotechnology	3.5863 of 5 stars	3.4	4.0	2.0	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNFT GENFIT	3.00	Buy	$13.00	238.10% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
IMNM Immunome	3.00	Buy	$23.33	123.29% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	451.00% Upside

Current Analyst Ratings Breakdown

Latest GNFT, IMNM, GYRE, and VIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00
5/22/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00
5/12/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $14.00
4/17/2025	VIR Vir Biotechnology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $21.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNFT GENFIT	$76.77M	2.50	$0.07 per share	54.83	$1.50 per share	2.56
GYRE Gyre Therapeutics	$105.76M	6.55	$0.20 per share	37.52	$1.05 per share	7.04
IMNM Immunome	$9.04M	100.58	N/A	N/A	$2.27 per share	4.60
VIR Vir Biotechnology	$74.21M	10.23	N/A	N/A	$8.35 per share	0.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/24/2025 (Estimated)
GYRE Gyre Therapeutics	$12.09M	$0.02	185.25	∞	N/A	7.20%	9.73%	7.66%	8/12/2025 (Estimated)
IMNM Immunome	-$292.96M	-$3.18	0.00	N/A	N/A	-1,875.21%	-71.65%	-60.36%	8/11/2025 (Estimated)
VIR Vir Biotechnology	-$521.96M	-$4.22	0.00	N/A	N/A	-2,769.04%	-47.46%	-39.33%	7/30/2025 (Estimated)

Latest GNFT, IMNM, GYRE, and VIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	GYRE Gyre Therapeutics	$0.03	N/A	N/A	N/A	$30.80 million	N/A
8/11/2025	Q2 2025	IMNM Immunome	-$0.52	N/A	N/A	N/A	$1.03 million	N/A
8/7/2025	Q2 2025	VIR Vir Biotechnology	-$0.83	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/9/2025	Q1 2025	GYRE Gyre Therapeutics	$0.03	$0.03	N/A	N/A	$28.40 million	$22.06 million
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNFT GENFIT	0.08	1.23	1.23
GYRE Gyre Therapeutics	N/A	3.60	3.19
IMNM Immunome	N/A	10.49	10.49
VIR Vir Biotechnology	N/A	6.79	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNFT GENFIT	2.24%
GYRE Gyre Therapeutics	23.99%
IMNM Immunome	44.58%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
GNFT GENFIT	4.20%
GYRE Gyre Therapeutics	10.00%
IMNM Immunome	8.60%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
GYRE Gyre Therapeutics	40	93.76 million	84.38 million	No Data
IMNM Immunome	40	87.01 million	79.53 million	Optionable
VIR Vir Biotechnology	580	138.24 million	116.12 million	Optionable

GNFT, IMNM, GYRE, and VIR Headlines

Recent News About These Companies

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

July 14 at 10:11 AM | finance.yahoo.com

Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Raymond James Financial

July 13, 2025 | americanbankingnews.com

Raymond James Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation

July 12, 2025 | msn.com

Vir Biotechnology (NASDAQ:VIR) Now Covered by Analysts at Raymond James Financial

July 11, 2025 | marketbeat.com

Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?

July 10, 2025 | zacks.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $32.86 Consensus Price Target from Brokerages

July 10, 2025 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Trading Up 9.2% - What's Next?

July 9, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 7, 2025 | marketbeat.com

Vicki L. Sato Sells 22,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

July 3, 2025 | insidertrades.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 22,000 Shares of Stock

July 2, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by State of Alaska Department of Revenue

June 30, 2025 | marketbeat.com

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

June 25, 2025 | finance.yahoo.com

Janet Napolitano Sells 3,200 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

June 3, 2025 | insidertrades.com

Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology

May 29, 2025 | investing.com

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025 | businesswire.com

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs

May 22, 2025 | fiercebiotech.comF

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

May 22, 2025 | benzinga.com

Vir’s hepatitis B combo falls short in Phase II trial

May 12, 2025 | msn.com

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025 | businesswire.com

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint

May 10, 2025 | finance.yahoo.com

Why Vir Biotechnology, Inc.’s (VIR) Stock Is Down 5.45%

May 10, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNFT, IMNM, GYRE, and VIR Company Descriptions

GENFIT NASDAQ:GNFT

$3.84 +0.01 (+0.13%)

Closing price 03:55 PM Eastern

Extended Trading

$3.78 -0.07 (-1.79%)

As of 04:52 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Gyre Therapeutics NASDAQ:GYRE

$7.39 -0.02 (-0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$7.38 -0.01 (-0.20%)

As of 07:33 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Immunome NASDAQ:IMNM

$10.45 +0.78 (+8.07%)

Closing price 04:00 PM Eastern

Extended Trading

$10.47 +0.02 (+0.19%)

As of 07:35 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Vir Biotechnology NASDAQ:VIR

$5.49 +0.08 (+1.48%)

Closing price 04:00 PM Eastern

Extended Trading

$5.55 +0.06 (+1.09%)

As of 07:21 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time